PMID- 15890413
OWN - NLM
STAT- MEDLINE
DCOM- 20051011
LR  - 20191210
IS  - 0165-1781 (Print)
IS  - 0165-1781 (Linking)
VI  - 135
IP  - 1
DP  - 2005 May 15
TI  - Condensed version of the Quality of Life Scale for schizophrenia for use in 
      outcome studies.
PG  - 65-75
AB  - The Quality of Life Scale (QLS(21)) is widely used in clinical trials involving 
      schizophrenia patients. This study aimed to identify a core subset of QLS(21) 
      items that maintains the validity and psychometric properties of the complete 
      version. A parsimonious subset of items from the QLS(21) that can accurately 
      predict the total scale score was sought and evaluated in 133 schizophrenia 
      patients, using the heuristic algorithm for a regression model. Two additional 
      data sets were used for model validation: a subset of 124 patients who 
      participated in the model construction and who completed the QLS(21) 1 year later 
      as well as a new sample of 40 inpatients. Patients were examined with the 
      Positive and Negative Syndrome Scale (PANSS), the Quality of Life Enjoyment and 
      Satisfaction Questionnaire (Q-LES-Q), the Talbieh Brief Distress Inventory 
      (TBDI), the Extrapyramidal Symptom Rating Scale (ESRS) and the Global Assessment 
      of Functioning Scale (GAF). Using only five QLS items (social initiatives, 
      adequacy, acquaintances, motivation, and time utilization; QLS(5)) as predictors, 
      the correlation was 0.9805 between the predicted and true QLS totals. Two 
      validation samples confirmed this finding. Additional analyses indicate that the 
      QLS(5) exhibited similar performance to the QLS(21) regarding construct validity, 
      test-retest reliability and responsiveness to changes over time. Thus, the 
      five-item condensed Quality of Life Scale for schizophrenia maintains the 
      validity of the full QLS, and has the advantage of shorter administration time. 
      Utilization of the revised QLS(5) in routine care and clinical trials may 
      potentially facilitate evaluation of treatment outcomes in schizophrenia.
FAU - Ritsner, Michael
AU  - Ritsner M
AD  - Pathological Behavior and Psychobiology Research Laboratory, Sha'ar Menashe 
      Mental Health Center, Hadera, Israel. ritsner@shaar-menashe.org.il
FAU - Kurs, Rena
AU  - Kurs R
FAU - Ratner, Yael
AU  - Ratner Y
FAU - Gibel, Anatoly
AU  - Gibel A
LA  - eng
PT  - Journal Article
PT  - Validation Study
PL  - Ireland
TA  - Psychiatry Res
JT  - Psychiatry research
JID - 7911385
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Affect
MH  - Basal Ganglia Diseases/epidemiology
MH  - Depression/diagnosis/epidemiology
MH  - Diagnostic and Statistical Manual of Mental Disorders
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Psychometrics/methods
MH  - Psychotic Disorders/diagnosis/epidemiology
MH  - Quality of Life/*psychology
MH  - Schizophrenia/epidemiology/*therapy
MH  - *Surveys and Questionnaires
MH  - Treatment Outcome
EDAT- 2005/05/14 09:00
MHDA- 2005/10/12 09:00
CRDT- 2005/05/14 09:00
PHST- 2004/04/13 00:00 [received]
PHST- 2004/12/26 00:00 [revised]
PHST- 2005/01/15 00:00 [accepted]
PHST- 2005/05/14 09:00 [pubmed]
PHST- 2005/10/12 09:00 [medline]
PHST- 2005/05/14 09:00 [entrez]
AID - S0165-1781(05)00063-6 [pii]
AID - 10.1016/j.psychres.2005.01.007 [doi]
PST - ppublish
SO  - Psychiatry Res. 2005 May 15;135(1):65-75. doi: 10.1016/j.psychres.2005.01.007.